Quantumscape Corp vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Quantumscape Corp trades at $4.63 (market cap $2.78B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.34 (market cap $2.28B). The key difference: Quantumscape Corp is the larger of the two by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Quantumscape Corp nearer its low. Which is the better fit depends on your goals.
| QS | SLS | |
|---|---|---|
Market Cap | $2.78B | $2.28B |
Volume | 11,236,221 | 3,128,960 |
Sector | Consumer Cyclical | Health |
52-Week High | $18.44 | $15.46 |
52-Week Low | $4.52 | $1.39 |
Typical Hold Time | 37 Days | — |
Enterprise Value | $1.99B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
QuantumScape (QS) trades at $4.58, down 1.51% on the day, with a bearish technical outlook and no current revenue generation. The company reported a net loss of $435.05 million in 2025 and faces significant execution risks as it develops solid-state battery technology. Analyst sentiment is cautious with 73% hold ratings, though the consensus price target of $10.35 suggests potential upside if commercialization milestones are met.
QS represents a high-risk, high-reward opportunity in the pre-revenue EV battery space. The primary investment thesis hinges on successful commercialization of solid-state batteries by 2029, but competition and execution delays pose substantial risks. Current negative ROE of -39.08% and cash burn require careful monitoring of funding runway and partnership developments with automotive manufacturers.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
QuantumScape Corp is engaged in the development of next-generation solid-state lithium-metal batteries for use in electric vehicles. It developed anode-less cell design, which delivers high energy density while lowering material costs and simplifying manufacturing.
Read more on QS →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →